Another possibility is that epigenetic silencing of MLH1 coincides with particular mutations, such as the BRAF V600E mutation (Donehower et al., 2013), which represents an established negative predictor of response to targeted anti-EGFR therapies in advanced CRC (Richman et al., 2009). Here, MLH1 is linked to colorectal carcinoma.